Advertisement

Protease Inhibitors (PIs)

*generic version available

E experimental


DRUG Aptivus
GENERIC NAME tipranavir
PHARMACEUTICAL COMPANY Boehringer Ingelheim
DRUG Crixivan
GENERIC NAME indinavir
PHARMACEUTICAL COMPANY Boehringer Ingelheim
DRUG Evotaz
GENERIC NAME atazanavir + cobicistat
PHARMACEUTICAL COMPANY Bristol-Myers Squibb
DRUG Invirase
GENERIC NAME saquinavir
PHARMACEUTICAL COMPANY Genentech, a division of Roche
DRUG Kaletra
GENERIC NAME lopinavir + ritonovir
PHARMACEUTICAL COMPANY AbbVie
DRUG Lexiva
GENERIC NAME fosamprenavir
PHARMACEUTICAL COMPANY ViiV Healthcare
DRUG Norvir
GENERIC NAME ritonavir
PHARMACEUTICAL COMPANY AbbVie
DRUG Prezcobix
GENERIC NAME darunavir + cobicistat
PHARMACEUTICAL COMPANY Janssen Therapeutics
DRUG Prezista
GENERIC NAME darunavir
PHARMACEUTICAL COMPANY Janssen Therapeutics
DRUG Reyataz
GENERIC NAME atazanavir
PHARMACEUTICAL COMPANY Bristol-Myers Squibb
DRUG Viracept
GENERIC NAME nelfinavir
PHARMACEUTICAL COMPANY ViiV Healthcare

What are Protease Inhibitors (PIs)?

When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. The CD4 cell is then "programmed" to make new HIV genetic material and HIV proteins. The proteins must be cut up by the HIV protease—a protein-cutting enzyme—to make functional new HIV particles. PIs block the protease enzyme and prevent the cell from producing new viruses. It is recommended that they be used in combination with at least two other HIV drugs to treat HIV infection.

Last Revised: January 13, 2016


Advertisement

Hot topics